瘤性病毒OVV-03通过免疫调节和特定的HER2上调增强了针对质母细胞瘤的CAR-T细胞疗法
Yi Tang1, Qinzhi E1, Liang Ma2
1Department of Neurosurgery, The Fourth Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Oncoimmunology
|January 7, 2026
概括
一种新型的瘤病毒,OVV-03,通过杀死癌细胞和重新编程瘤微环境,有效地准质母细胞瘤. 它在与CAR-T细胞疗法结合使用时显示出有前途,可改善患者的存活率.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 病毒学 病毒学
背景情况:
- 质母细胞瘤 (GBM) 由于耐药性和免疫抑制,存在重大治疗挑战.
- 抗瘤病毒疗法是克服这些挑战的潜在策略.
研究的目的:
- 为质母细胞瘤治疗设计和评估一种新型的HER2-武装型囊泡性口腔炎病毒 (OVV-03).
- 研究OVV-03抗瘤活性的机制及其与CAR-T细胞的协同作用.
主要方法:
- 改造的OVV-03,一种HER2武装的型囊泡性口腔炎病毒.
- 在GBM细胞中评估了OVV-03的传染性,细胞毒性和亡诱导.
- 在使用瘤生长,生存和免疫细胞透指标的小鼠GBM模型中评估了OVV-03的疗效.
- 利用单细胞RNA测序来分析免疫微环境调制.
- 研究了OVV-03对PD-L1表达和相关信号通路的影响.
- 评估了OVV-03与CAR-T细胞在 ортотоп GBM 模型中的协同作用.
主要成果:
- OVV-03对GBM细胞表现出强烈的传染性和细胞毒性,诱导了细胞亡并抑制了增殖.
- 在体内,OVV-03显著抑制瘤生长,改善存活率,增加CD8+ T细胞透.
- 单细胞RNA测序揭示了OVV-03增强细胞毒性T细胞活性和抑制免疫抑制途径的能力,包括PD-L1/PD-1.
- OVV-03通过JNK-c-Fos/c-Jun轴向下调节了PD-L1.
- OVV-03与向HER2或B7H3的CAR-T细胞协同作用,导致优异的瘤回归和延长生存时间.
结论:
- OVV-03显示出对质母细胞瘤有强大的直接瘤治疗和免疫激活作用.
- OVV-03调节瘤免疫微环境,特别是通过降低PD-L1.1的调节.
- 将OVV-03与CAR-T细胞结合起来,是针对GBM的一种非常有前途的免疫病毒疗法策略.
相关概念视频
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Cancer Vaccines
946
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
946
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cytotoxic T Cells-mediated Immune Response
6.5K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.5K


